Anthem Biosciences IPO Date, Price, GMP, Allotment & Review – Key Details Inside

Anthem Biosciences IPO is scheduled to open for subscription on July 14, 2025, and will close on July 16, 2025. The basis of allotment will be finalized on July 17, 2025, followed by refunds and credit to Demat accounts on July 18, 2025. The company is expected to make its stock market debut on July 21, 2025, with listings on both BSE and NSE.

Anthem Biosciences is launching a Book Build Issue IPO to raise approximately ₹3,395 crores, entirely through an offer for sale of 5.96 crore equity shares with a face value of ₹2 each. The price band is fixed at ₹540 to ₹570 per share, and the lot size for retail investors is 26 shares, requiring a minimum investment of ₹14,040. For non-institutional investors, the small NII (sNII) category starts at 14 lots (364 shares) with an investment of ₹2,07,480, and the big NII (bNII) starts at 68 lots (1,768 shares).

The retail quota is 35%, while Qualified Institutional Buyers (QIBs) get 50% and Non-Institutional Investors (HNIs) are allotted 15%. Financially, the company has shown strong growth with a revenue jump from ₹1,483.07 crores in FY 2024 to ₹1,930.29 crores in FY 2025, and a rise in net profit from ₹367.31 crores to ₹451.26 crores in the same period. Given its robust financial performance and market potential, Anthem Biosciences IPO is considered a long-term investment opportunity worth considering.

Anthem Biosciences IPO Opens July 14: Price, Dates, Lot Size, and Details

About Anthem Biosciences IPO

Anthem Biosciences Limited, started in 2006, is one of India’s fastest-growing and innovation-driven CRDMO (Contract Research, Development, and Manufacturing Organization) companies. The company offers full services across the entire drug life cycle – from discovery and development to manufacturing – for both small molecules and biologics. They provide advanced research and manufacturing solutions to a wide range of customers, including small biotech startups and large pharmaceutical giants across the globe.

Read Also  Arisinfra Solutions IPO: Date, Price, GMP, Allotment & Review – Key Details Inside

The company is known for making fermentation-based APIs like probiotics, enzymes, peptides, nutritional ingredients, vitamin analogues, and biosimilars. As of September 30, 2024, Anthem Biosciences had over 425 active customers across more than 44 countries, including the USA, Europe, and Japan, and had handled 196 projects – including early and late-phase research and commercial manufacturing.

Their team of around 600 skilled employees includes scientists like medicinal chemists, microbiologists, molecular biologists, and chemical engineers. The company also holds 8 patents (1 in India and 7 abroad) and has filed 24 more patent applications globally. Anthem’s strong focus on innovation, long-term customer relations, and a professional leadership team makes it a trusted partner for pharma and biotech companies worldwide.

Anthem Biosciences IPO Overview

IPO DetailsInformation
Face Value₹2 per equity share
Price Band₹540 to ₹570 per share
Lot Size26 Shares
Total Issue Size5,95,61,404 shares (Approx ₹3,395 Cr)
Offer for SaleEntire issue (No fresh issue)
Employee Discount₹50 per share
Issue TypeBook Building IPO
Listing AtBSE & NSE
Retail Investor QuotaNot more than 35%
QIB QuotaNot more than 50%
NII (HNI) QuotaNot more than 15%
Pre-Issue Shareholding55,90,77,100 shares
Post-Issue Shareholding55,90,77,100 shares (no change)

Anthem Biosciences IPO Dates

EventDate (Day)
IPO Open DateJuly 14, 2025 (Monday)
IPO Close DateJuly 16, 2025 (Wednesday)
Basis of AllotmentJuly 17, 2025 (Thursday)
RefundsJuly 18, 2025 (Friday)
Credit to Demat AccountJuly 18, 2025 (Friday)
IPO Listing DateJuly 21, 2025 (Monday)

Anthem Biosciences IPO Prospectus

DRHPClick here
RHPClick here

Anthem Biosciences IPO Lot Size

The lot size for the Anthem Biosciences IPO is set at 26 shares, and investors can apply in multiples of this lot. The minimum investment for retail investors starts at ₹14,820, while high net-worth individuals (HNIs) can invest significantly higher based on their category. The table below shows the lot-wise investment details:

CategoryLotsSharesAmount
Retail (Min)126₹14,820
Retail (Max)13338₹1,92,660
S-HNI (Min)14364₹2,07,480
S-HNI (Max)671,742₹9,92,940
B-HNI (Min)681,768₹10,07,760

Anthem Biosciences IPO Promoter Holding

The promoters of Anthem Biosciences are Ajay Bhardwaj, Ganesh Sambasivam, K Ravindra Chandrappa, and Ishaan Bhardwaj. Their collective shareholding stands at 77.23% before the IPO, which will slightly reduce to 74.68% post-issue, as the IPO is a complete offer for sale.

Read Also  Aegis Vopak Terminals IPO: Date, Price, GMP, Allotment & Review – Key Details Inside

Anthem Biosciences IPO Financial Performance

Financial Metric (₹ in Crore)FY 2025FY 2024FY 2023
Total Assets2,807.582,398.112,014.46
Revenue1,930.291,483.071,133.99
Profit After Tax (PAT)451.26367.31385.19
EBITDA683.78519.96446.05
Net Worth2,409.861,924.661,740.67
Reserves and Surplus2,298.051,815.391,628.88
Total Borrowings108.95232.53125.06

Object of the Issue

  • To be Updated

Anthem Biosciences IPO Review

  • Sharekhan –
  • Canara Bank –
  • DRChoksey FinServ –
  • Emkay Global –
  • Hem Securities –
  • IDBI Capital –
  • Marwadi Shares –
  • Nirmal Bang –
  • SBICAP Securities –
  • SMC Global –
  • Sushil Finance –
  • Swastika Investmart –
  • Ventura Securities –
  • Geojit –
  • Reliance Securities –
  • Capital Market –
  • BP Wealth –
  • ICICIdirect –
  • Choice Broking –
Spread the love

Leave a Comment